EZH2 and small cell lung carcinoma: Modulation of epigenetic pathways (such as enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2)) has been proposed as a means of not only treating patients with transformed SCLC but also preventing SCLC transformation.